Iododoxorubicin

Iododoxorubicin is a derivative of Doxorubicin (HY-15142A) and anticancer agent. Iododoxorubicin has stronger activity against Lewis lung carcinoma than Doxorubicin[1][2].

Product Specifications

CAS Number

[83997-75-5]

UNSPSC

12352005

Target

Drug Derivative

Related Pathways

Others

Field of Research

Cancer

Smiles

[H][C@]1(O[C@H]2C[C@@](CC3=C(C(C(C4=C5C(OC)=CC=C4)=O)=C(C(O)=C23)C5=O)O)(C(CO)=O)O)C[C@@H]([C@@H]([C@@H](O1)C)I)N

Molecular Formula

C27H28INO10

Molecular Weight

653.42

References & Citations

[1]Berger I, et al. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d (TGTACA) and d (CGATCG) . Nucleic Acids Res. 1995 Nov 11;23 (21) :4488-94. |[2]Twelves CJ, et al. Dobbs NA, Lawrence MA, Ramirez AJ, Summerhayes M, Richards MA, Towlson KE, Rubens RD. Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer. 1994 Apr;69 (4) :726-31.